Press Releases
Media Contact:
Lorie Calvo
425-608-3008
Northwest Biotherapeutics to Present at the Williamsburg BioProcessing Foundation Conference
BOTHELL, WA– September 22, 2005 – Northwest Biotherapeutics (OTCBB: NWBT.OB) today announced that the company will be presenting at the Williamsburg BioProcessing Foundation Cell and Tissue BioProcessing Conference 10th Annual Meeting in Newport Beach, California being held September 26th – 28th, 2005.
The presentation will be given by Marnix Bosch, Ph.D., Vice President, Vaccine Research and Development of Northwest Biotherapeutics. Dr. Bosch’s presentation is entitled, “DCVax®, a Versatile Dendritic Cell-Based Therapeutic Vaccine Platform for Cancer, and its Application to the Clinic,” and is scheduled for Monday, September 26th at 8:30 am in the Four Seasons Newport Beach Hotel.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell based vaccines, and therapeutic antibodies. The Company's three lead product candidates are:
DCVax®-Prostate, a personalized dendritic cell vaccine for treatment of hormone independent non-metastatic prostate cancer, which is entering a Phase III clinical trial; DCVax®-Brain, a personalized dendritic cell vaccine for treatment of newly diagnosed Glioblastoma multiforme, which is entering a large Phase II clinical trial; and CXCR4 a therapeutic monoclonal antibody for treatment of solid tumors, that is in late preclinical development.
Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “expects,” “believes,” “intends,” and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company’s ability to raise additional capital, risks related to the Company’s ability to enroll patients in the planned Phase III trial of DCVax®-Prostate and complete the trial on a timely basis, the uncertainty of the clinical trials process and whether DCVax®-Prostate will demonstrate safety and efficacy, risks associated with the planned Phase II clinical trial of DCVax®-Brain and the planned Phase I clinical trial for non-small cell lung cancer and head and neck cancer, and the timely performance of third parties. Additional information on these and other factors, which could affect the Company’s results, is included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company’s SEC filings that may cause actual results to differ materially those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
|
